Weight loss products—whether prescription GLP-1/GIP agonists like tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy), research peptides such as AOD-9604, or emerging dual/triple incretin mimetics—work best when combined with purposeful lifestyle adjustments. By 2026 clinical trials, real-world registries, and user reports consistently show that medication alone produces good results, but adding targeted diet, exercise, sleep, stress […]